Home T Cells Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration

Tissue-Regulation-Experts-at-Trex-Bio — TRexBio has launched its second collaboration with a biopharma giant, inking a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Cos. of Johnson & Johnson. The companies have agreed to use TRexBio’s platform to discover novel targets that address unmet needs in TRex’s core therapeutic area of immunology and inflammation (I&I). [TRexBio]

Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration

Four years after a pivotal cocktail napkin meeting, companies to discover novel targets in immunology and inflammation

By Alex Philippidis

January 10, 2022

TRexBio has launched its second collaboration with a biopharma giant, inking a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Cos. of Johnson & Johnson. The companies have agreed to use TRexBio’s platform to discover novel targets that address unmet needs in TRex’s core therapeutic area of immunology and inflammation (I&I). [TRexBio]

TRexBio’s platform, dubbed Deep Biology, helps identify and characterize novel targets by mapping human tissue Treg behavior to disease processes. As key regulators of the immune system, Tregs play important roles in tissue inflammation and mediation of tissue healing. Deep Biology has identified more than 20 novel tissue-focused targets so far. The platform has three pillars: A high-resolution map or "Atlas" of tissue Treg pathways in health and disease, computational tools, and a suite of functional assays in human primary Tregs . . .